Trial Profile

A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study (AHELP) of Apatinib in Patients With Hepatocellular Carcinoma After Systemic TherapyChemotherapy and/or Targeted Therapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivoceranib (Primary)
Indications Carcinoma; Liver cancer
Focus Registrational; Therapeutic Use
Acronyms AHELP
Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

31 Jan 2021 Status changed from active, no longer recruiting to completed.
31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
04 Jul 2017 Planned number of patients changed from 360 to 400.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com